Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Kopp

Showing results (201-210 of 217) with videos related to

Pageof 22
Sort By:
Cardio-Oncology (London, England)|March 11, 2020
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology GroupLisa M Kopp, Richard B Womer, Cindy L Schwartz, et al.
Cancer|May 12, 2017
Clinical trial enrollment of adolescents and young adults with sarcomaLara E Davis, Katherine A Janeway, Aaron R Weiss, et al.
Journal of Adolescent and Young Adult Oncology|February 1, 2023
Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working GroupSusan L Whiteway, Aaron R Weiss, Safia K Ahmed, et al.
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg|March 8, 2016
[The flexibility of family medicine]C Minguet, A Aubrege, M Aubart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2023
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood CancerEric J Chow, Sanjeev Aggarwal, David R Doody, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
Journal of Personality Assessment|March 26, 2020
Measuring Implicit Motives with the Picture Story Exercise (PSE): Databases of Expert-Coded German Stories, Pictures, and Updated Picture NormsFelix D Schönbrodt, Birk Hagemeyer, Veronika Brandstätter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Journal of Adolescent and Young Adult Oncology|September 13, 2021
Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321Viswatej Avutu, Aaron R Weiss, Damon R Reed, et al.
ESMO Open|July 6, 2026
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)G Roviello, F Ciccimarra, F Urabe, et al.
Pageof 22

Showing results (201-210 of 217) with videos related to

Sort By:
Pageof 22
Cardio-Oncology (London, England)|March 11, 2020
Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children's Oncology GroupLisa M Kopp, Richard B Womer, Cindy L Schwartz, et al.
Cancer|May 12, 2017
Clinical trial enrollment of adolescents and young adults with sarcomaLara E Davis, Katherine A Janeway, Aaron R Weiss, et al.
Journal of Adolescent and Young Adult Oncology|February 1, 2023
Joint Adult and Pediatric Working Group as a Successful Platform to Strengthen Adolescent and Young Adult (AYA) Clinical Trial Collaboration: A Report from the NCTN/SARC AYA Clinical Trials Sarcoma Working GroupSusan L Whiteway, Aaron R Weiss, Safia K Ahmed, et al.
Bulletin De La Societe Des Sciences Medicales Du Grand-Duche De Luxembourg|March 8, 2016
[The flexibility of family medicine]C Minguet, A Aubrege, M Aubart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2023
Dexrazoxane and Long-Term Heart Function in Survivors of Childhood CancerEric J Chow, Sanjeev Aggarwal, David R Doody, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 studyJ N Graff, M Burotto, P C Fong, et al.
Journal of Personality Assessment|March 26, 2020
Measuring Implicit Motives with the Picture Story Exercise (PSE): Databases of Expert-Coded German Stories, Pictures, and Updated Picture NormsFelix D Schönbrodt, Birk Hagemeyer, Veronika Brandstätter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 studyC Gratzke, M Özgüroğlu, A Peer, et al.
Journal of Adolescent and Young Adult Oncology|September 13, 2021
Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321Viswatej Avutu, Aaron R Weiss, Damon R Reed, et al.
ESMO Open|July 6, 2026
Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study)G Roviello, F Ciccimarra, F Urabe, et al.
Pageof 22